Markets

Insider Trading

Hedge Funds

Retirement

Opinion

14 Best Medical Stocks To Invest In According to Hedge Funds

In this piece, we will take a look at the 14 best medical stocks to invest in according to hedge funds. If you want to skip our overview of the medical and healthcare industry, then you can take a look at the 5 Best Medical Stocks To Invest In According to Hedge Funds.

The medical and healthcare industry is one of the biggest in the world. The medical industry is assured of a steady demand for its products and services simply due to the fact that human beings are biological creatures. This means that medical stocks such as Pfizer Inc. (NYSE:PFE) and hospital stocks such as Tenet Healthcare Corporation (NYSE:THC) are some of the biggest in the world. It also means that these stocks have the potential to capitalize on trends that can suddenly appear due to crises such as the coronavirus pandemic. While the fast paced nature of news cycles in the 21st century means that public focus quickly changes focus, in the immediate aftermath of the pandemic’s rapid spread in 2020, investors were fretting and would have given an arm and a leg to prod the crystal ball into telling them which medical stock would be the right bet when it came to navigating the global healthcare prices.

As time would tell, medical stocks like Pfizer and the Cambridge, Massachusetts based biotechnology company Moderna, Inc. (NASDAQ:MRNA) were some of the hottest due to their vaccines. During the roughly year and a half between December 2019 and September 2021, Moderna’s shares appreciated by a whopping 429% on the stock market –  a result that shows that even small bets made at just the right time can yield juicy profits for investors from all walks of life. Pfizer’s stock gained a more modest 50% during the same time period; but the difference between these gains is one that is understandable since Pfizer’s current market capitalization of $155 billion is more than four times of Moderna’s.

Additionally, another key difference between Moderna and Pfizer also applies to the broader categories of medical stocks that include high growth sectors such as biotechnology and somewhat more stable ones like medical device manufacturers and hospital operators. Pfizer, like its peers Eli Lilly and Company (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), and Merck & Co., Inc. (NYSE:MRK), benefits from one of the classic principles of business management, a.k.a, diversification. These medical stocks have the luxury of sizeable balance sheets that allow them to participate in markets for simple medicines that can be produced at mass scale like blood thinners, as well as medical industry segments requiring massive capital expenditure and research capabilities such as biotechnology and genetic engineering.

However, with genetic engineering having entered the conversation, this particular area of medicine benefits from smaller companies that are able to laser focus on being able to change the very ‘code’ of the human body. At the same time, while the glitzy and glamorous nature of high technology areas such as artificial intelligence means that the bulk of public and media attention remains focused on them, recent months have also seen medical stocks involved in the genomics industry make strides. If you’re interested, you can check out 12 Best Genomics Stocks To Buy Now for a detailed look at these stocks.

So what’s big in genomics? Well, medical stocks Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and BridgeBio Pharma, Inc. (NASDAQ:BBIO) scored big wins in December 2023 when the Food and Drug Administration (FDA) approved the first therapies for sickle cell disease that use gene therapy. According to Yale Medicine, Vertex’s Casgevy essentially ‘slices’ a patient’s DNA to improve odds of fighting sickle cell disease while BBIO’s Lyfgenia introduces substances that improve blood health.

Yet, mega medical stocks Eli Lilly and Novo Nordisk A/S (NYSE:NVO) are also all the hype these days as their medications finally provide an off the shelf solution to lose weight. So much so that Eli Lilly’s shares are up by a whopping 380% since 2020 while Novo Nordisk’s stock has gained 275% over the same time period. Weight loss drugs are now a no longer a thing of the future, and investors have baked in their potential into medical stocks as well. You can read 11 Best Weight Loss Stocks To Invest In for more details.

With these details, let’s look at some top medical stocks. Some notable picks are Thermo Fisher Scientific Inc. (NYSE:TMO), Danaher Corporation (NYSE:DHR), and UnitedHealth Group Incorporated (NYSE:UNH).

A veterinarian conducting a physical exam on a four-legged patient in a veterinary hospital, highlighting the company’s work in veterinary health.

Our Methodology

To make our list of the best medical stocks to buy, we ranked the forty most valuable healthcare stocks by the number of hedge funds that had bought the shares as of Q4 2023 end. Out of these, the top stocks were selected as the best medical stocks.

For these best medical stocks, we used hedge fund sentiment. Hedge funds’ top 10 consensus stock picks outperformed the S&P 500 Index by more than 140 percentage points over the last 10 years (see the details here). That’s why we pay very close attention to this often-ignored indicator.

14 Best Medical Stocks To Invest In According to Hedge Funds

14. Boston Scientific Corporation (NYSE:BSX)

Number of Q4 2023 Hedge Fund Shareholders: 71

Boston Scientific Corporation (NYSE:BSX) is a medical devices company whose products help with disease diagnosis, disease management, imaging, and other areas. The shares are rated Strong Buy on average, and the average analyst share price target is $70.82.

As of Q4 2023 end, 71 out of the 933 hedge funds profiled by Insider Monkey had held a stake in Boston Scientific Corporation (NYSE:BSX). Ken Griffin’s Citadel Investment Group was the biggest Boston Scientific Corporation (NYSE:BSX) shareholder through its $519 million investment.

13. HCA Healthcare, Inc. (NYSE:HCA)

Number of Q4 2023 Hedge Fund Shareholders: 72

HCA Healthcare, Inc. (NYSE:HCA) serves as the customer facing end of the medical supply chain since it owns and operates hospitals all over the U.S. It’s been performing well on the financial front as of late by having beaten analyst EPS estimates in three out of its four latest quarters. To wit, the shares are also rated Strong Buy on average, and the average analyst share price target is $324.

During Q4 2023, 72 out of the 933  hedge funds part of Insider Monkey’s database had bought and owned HCA Healthcare, Inc. (NYSE:HCA)’s shares. Jean-Marie Eveillard’s First Eagle Investment Management was the biggest investor in our database as it owned $1.2 billion worth of shares.

HCA Healthcare, Inc. (NYSE:HCA) joins Danaher Corporation (NYSE:DHR), Thermo Fisher Scientific Inc. (NYSE:TMO), and UnitedHealth Group Incorporated (NYSE:UNH) in our list of the best medical stocks to buy.

12. AbbVie Inc. (NYSE:ABBV)

Number of Q4 2023 Hedge Fund Shareholders: 76

AbbVie Inc. (NYSE:ABBV) is a healthcare and pharmaceutical company headquartered in Chicago, Illinois. It scored a win in February 2024 when its medicine for Parkinson’s disease was cleared for sale in Canada.

As of December 2023 end, out of the 910 hedge funds covered by Insider Monkey’s research, 76 had invested in AbbVie Inc. (NYSE:ABBV). Paul Marshall and Ian Wace’s Marshall Wace LLP was the biggest investor as it owned 3.1 million shares that were worth $491 million.

11. The Cigna Group (NYSE:CI)

Number of Q4 2023 Hedge Fund Shareholders: 76

The Cigna Group (NYSE:CI) marks the entry of the financial domain into our list of the best medical stocks since it is a healthcare plan provider. It’s also one of the stronger stocks on our list when it comes to dividends as the firm announced a $1.40 dividend per share for a 1.50% yield in February 2024.

Insider Monkey scanned 933 hedge fund portfolios for their December quarter of 2023 shareholdings to discover that 76 had invested in the firm. The largest The Cigna Group (NYSE:CI) stakeholder is Larry Robbins’s Glenview Capital due to its $641 million stake.

10. Pfizer Inc. (NYSE:PFE)

Number of Q4 2023 Hedge Fund Shareholders: 79

Pfizer Inc. (NYSE:PFE) is one of the biggest pharmaceutical companies in the world. The firm expanded its social credibility earlier this month when it teamed up with the American Cancer Association (ACA) as part of an impressive $15 million initiative to increase awareness about cancer screenings.

Insider Monkey dug through 933 hedge fund portfolios for their fourth quarter of 2023 investments and found that 79 were the firm’s investors. The largest Pfizer Inc. (NYSE:PFE)’s shareholder out of these is D. E. Shaw’s D E Shaw due to its $418 million investment.

9. Johnson & Johnson (NYSE:JNJ)

Number of Q4 2023 Hedge Fund Shareholders: 81

Johnson & Johnson (NYSE:JNJ) is the iconic American personal wellness and healthcare company with a storied past. The firm is having an eventful February 2024 as its CEO was grilled by U.S. Senators on the sensitive issue of high drug prices for working class Americans.

81 out of the 933 hedge funds covered by Insider Monkey’s Q4 2023 research had bought Johnson & Johnson (NYSE:JNJ)’s shares. Ken Fisher’s Fisher Asset Management was the biggest investor, owning 6.3 million shares that are worth $996 million.

Thermo Fisher Scientific Inc. (NYSE:TMO), Johnson & Johnson (NYSE:JNJ), Danaher Corporation (NYSE:DHR), and UnitedHealth Group Incorporated (NYSE:UNH) are some top medical stocks that hedge funds are piling into.

8. Intuitive Surgical, Inc. (NASDAQ:ISRG)

Number of Q4 2023 Hedge Fund Shareholders: 82

Intuitive Surgical, Inc. (NASDAQ:ISRG) is one of the most advanced medical stocks in the world since it is among a handful of companies with a successful surgical robot. The fourth quarter of 2023 saw the firm maintain its growth trajectory as the DaVinci platform grew procedures by 21%.

For their fourth quarter of 2023 investments, 82 out of the 933 hedge funds tracked by Insider Monkey were the firm’s shareholders. Intuitive Surgical, Inc. (NASDAQ:ISRG)’s largest hedge fund investor is Ken Fisher’s Fisher Asset Management through its $1.5 billion stake.

7. Elevance Health, Inc. (NYSE:ELV)

Number of Q4 2023 Hedge Fund Shareholders: 83

Elevance Health, Inc. (NYSE:ELV) provides healthcare coverage plans and is one of the older medical stocks on our list since it was set up in 1944. Like other healthcare plan providers, while it managed to beat analyst EPS estimates for 2023’s first three quarters, the fourth quarter ended up being an inevitable miss in hindsight.

During December 2023, 83 out of the 933 hedge funds part of Insider Monkey’s database were the firm’s investors. Elevance Health, Inc. (NYSE:ELV)’s largest stakeholder among these is Jean-Marie Eveillard’s First Eagle Investment Management as it owns $838 million worth of shares.

6. Humana Inc. (NYSE:HUM)

Number of Q4 2023 Hedge Fund Shareholders: 86

Humana Inc. (NYSE:HUM) is another healthcare plan provider. The firm was out with some bad news for investors in February 2024 when it revealed that federal rates for its products had disappointed. However, the firm did maintain guidance for 2025.

By the end of last year’s fourth quarter, 86 out of the 933 hedge funds covered by Insider Monkey’s research had bought a stake in Humana Inc. (NYSE:HUM). Ken Griffin’s Citadel Investment Group owned the biggest stake which was worth $688 million.

Click here to continue reading and check out 5 Best Medical Stocks To Invest In According to Hedge Funds.

Suggested articles:

Disclosure: None. 14 Best Medical Stocks To Invest In According to Hedge Funds is originally published on Insider Monkey.

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

  • The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
  • Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
  • Lifetime Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

  1. Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
  2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
  3. Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…